You are here

Circulating Vitamin D Levels and Alzheimer's Disease: A Mendelian Randomization Study in the IGAP and UK Biobank.

TitleCirculating Vitamin D Levels and Alzheimer's Disease: A Mendelian Randomization Study in the IGAP and UK Biobank.
Publication TypeJournal Article
Year of Publication2020
AuthorsWang L, Qiao Y, Zhang H, Zhang Y, Hua J, Jin S, Liu G
JournalJ Alzheimers Dis
Volume73
Issue2
Pagination609-618
Date Published2020
ISSN1875-8908
KeywordsAged, Aged, 80 and over, Alzheimer Disease, Biological Specimen Banks, Cognition Disorders, Databases, Factual, Female, Genome-Wide Association Study, Humans, Hydroxycholecalciferols, Male, Mendelian Randomization Analysis, Middle Aged, Nutritional Status, United Kingdom, Vitamin D, Vitamin D Deficiency
Abstract

Observational studies strongly supported the association of low levels of circulating 25-hydroxyvitamin D (25OHD) and cognitive impairment or dementia in aging populations. However, randomized controlled trials have not shown clear evidence that vitamin D supplementation could improve cognitive outcomes. In fact, some studies reported the association between vitamin D and cognitive impairment based on individuals aged 60 years and over. However, it is still unclear that whether vitamin D levels are causally associated with Alzheimer's disease (AD) risk in individuals aged 60 years and over. Here, we performed a Mendelian randomization (MR) study to investigate the causal association between vitamin D levels and AD using a large-scale vitamin D genome-wide association study (GWAS) dataset and two large-scale AD GWAS datasets from the IGAP and UK Biobank with individuals aged 60 years and over. Our results showed that genetically increased 25OHD levels were significantly associated with reduced AD risk in individuals aged 60 years and over. Hence, our findings in combination with previous literature indicate that maintaining adequate vitamin D status in older people especially aged 60 years and over, may contribute to slow down cognitive decline and forestall AD. Long-term randomized controlled trials are required to test whether vitamin D supplementation may prevent AD in older people especially those aged 60 years and may be recommended as preventive agents.

DOI10.3233/JAD-190713
Pubmed Linkhttps://www.ncbi.nlm.nih.gov/pubmed/31815694?dopt=Abstract
page_expoInternal
Alternate JournalJ Alzheimers Dis
PubMed ID31815694
Grant ListU24 AG021886 / AG / NIA NIH HHS / United States
503480 / MRC_ / Medical Research Council / United Kingdom
N01AG12100 / AG / NIA NIH HHS / United States
U01 AG032984 / AG / NIA NIH HHS / United States
R01 HL105756 / HL / NHLBI NIH HHS / United States
082604/2/07/Z / WT_ / Wellcome Trust / United Kingdom
R01 AG033193 / AG / NIA NIH HHS / United States

Theme by Danetsoft and Danang Probo Sayekti inspired by Maksimer